

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/666,696	09/19/2003	Ulrich Feige	A-527H	8548	
7590 05/18/2004			EXAMINER		
US Patent Operations/[TJG]			WESSENDORF, TERESA D		
Dept. 4300, M/S AMGEN INC.	5 27-4-A	ART UNIT	PAPER NUMBER		
One Amgen Center Drive			1639		
Thousand Oaks, CA 91320-1799			DATE MAILED: 05/18/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicatio	n No.	Applicant(s)				
		10/666,690	3	FEIGE ET AL.				
Office Action Summary		Examiner		Art Unit				
		T. D. Wess	endorf	1639				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
THE I - Exter after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REIMAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory per re to reply within the set or extended period for reply will, by state reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no ever reply within the statu- riod will apply and will atute, cause the appli	nt, however, may a repl tory minimum of thirty (in expire SIX (6) MONTH cation to become ABAN	y be timely filed 30) days will be considered time IS from the mailing date of this of NDONED (35 U.S.C. § 133).	ely. communication.			
Status								
1)[Responsive to communication(s) filed on	·						
2a) <u></u>	This action is FINAL . 2b) T	his action is no	on-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
5)□ 6)□ 7)□ 8)⊠ Applicati	Claim(s) <u>1-62</u> is/are pending in the applicated 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-62</u> are subject to restriction and/ ion Papers The specification is objected to by the Example to drawing(s) filed on is/are: a) are	drawn from con	uirement.	the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority (under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Infor	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB er No(s)/Mail Date			Mail Date prmal Patent Application (PT	ГО-152)			

Art Unit: 1639

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-21, drawn to a composition of matter.
- II. Claims 22-25, drawn to a DNA, vector and host cell.
- III. Claims 26-40, 42-51, drawn to a process for preparing a pharmacologically active compound.
- IV. Claim 41, drawn to a process with a derivatized compound.
- V. Claims 52-56, drawn to a composition with an effector molecule.
- VI. Claims 57-62, drawn to a process for preparing a composition with a randomize peptide that binds to a target epitope.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different

Art Unit: 1639

inventions are drawn to structurally different compounds with different effects and mode of actions.

Inventions III, IV and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to distinct methods comprising different components, modes of operation and functions or effects.

Inventions (I, II and V) and (III, IV and VI) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different compounds and different, distinct processes.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and the search required for Group I is not required for Groups II-VI, specifically the literature journals, restriction for examination purposes as indicated is proper.

Art Unit: 1639

Claims 1, 22, 26, 41, 52 and 57 are generic to a plurality of disclosed patentably distinct species comprising:

If any one of the Groups I-VI, above is elected, applicants are to elect a single species:

Composition (as recited in e.g., claim 1). Applicants are to elect a single species of the composition. Claim 2 is a subgenus. A species will recite all the variables of the formula. Also, whether the peptide composition is a monomer or multimer.

If Group III, is elected:

In addition to the composition above, applicants are to elect one species from each of subgroups A and B as follows:

- A). Selection process as recited in claim 27.
 - i. Yeast -based screening
 - ii. Rational design
 - iii. Protein structural analysis
 - iv. Phage display library screening
 - v. E. coli display library
 - vi. Ribosomal library
 - vii. Chemical peptide library

Application/Control Number: 10/666,696 Art Unit: 1639

- B). Protein of interest (as recited in e.g., claim 30 or 31. Note a species of the receptor is required. Cell surface is a genus.)
- B). Peptide as recited in claims 33-35 i.e., a species of e.g., EPO-mimics. (The species that can be selected in Tables 4-20 as recited in claim 39)

If Group IV, is elected:

In addition to the composition above, applicants are to elect:

Derivative of the compound as recited in claim 42 i.e., a species of the derivative.

If Group V or VI, is elected:

In addition to the composition above, applicants are to elect:

A). Effector molecule. Note that claim 52 lists recite a genus, not a species. A species is recited in e.g., claim 56 i.e., only one species.

Each of the species in the composition, for example, differs in structure and possibly effect. A prior art reference anticipating one species would not render obvious the other species.

Art Unit: 1639

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1639

Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. D. Wessendorf whose telephone number is(571) 272-0812. The examiner can normally be reached on Flexitime.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

T. D. Wessendorf Primary Examiner Art Unit 1639

Tdw May 17, 2004